BRIEF-RXI Pharmaceuticals says received notice of allowance for RXI-109 from USPTO
April 19, 2016 at 07:32 AM EDT
* RXI Pharmaceuticals says fortifies its novel RNAi patent portfolio with notice of allowance for lead clinical candidate RXI-109 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)